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Abstract
Background:  Genetic evidence for diversifying selection identified the Merozoite Surface
Protein1 block2 (PfMSP1 block2) as a putative target of protective immunity against Plasmodium
falciparum. The locus displays three family types and one recombinant type, each with multiple
allelic forms differing by single nucleotide polymorphism as well as sequence, copy number and
arrangement variation of three amino acid repeats. The family-specific antibody responses
observed in endemic settings support immune selection operating at the family level. However, the
factors contributing to the large intra-family allelic diversity remain unclear. To address this
question, population allelic polymorphism and sequence variant-specific antibody responses were
studied in a single Senegalese rural community where malaria transmission is intense and perennial.
Results: Family distribution showed no significant temporal fluctuation over the 10 y period
surveyed. Sequencing of 358 PCR fragments identified 126 distinct alleles, including numerous novel
alleles in each family and multiple novel alleles of recombinant types. The parasite population
consisted in a large number of low frequency alleles, alongside one high-frequency and three
intermediate frequency alleles. Population diversity tests supported positive selection at the family
level, but showed no significant departure from neutrality when considering intra-family allelic
sequence diversity and all families combined. Seroprevalence, analysed using biotinylated peptides
displaying numerous sequence variants, was moderate and increased with age. Reactivity profiles
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were individual-specific, mapped to the family-specific flanking regions and to repeat sequences
shared by numerous allelic forms within a family type. Seroreactivity to K1-, Mad20- and R033
families correlated with the relative family genotype distribution within the village. Antibody
specificity remained unchanged with cumulated exposure to an increasingly large number of alleles.
Conclusion: The Pfmsp1 block2 locus presents a very large population sequence diversity. The
lack of stable acquisition of novel antibody specificities despite exposure to novel allelic forms is
reminiscent of clonal imprinting. The locus appears under antibody-mediated diversifying selection
in a variable environment that maintains a balance between the various family types without
selecting for sequence variant allelic forms. There is no evidence of positive selection for intra-
family sequence diversity, consistent with the observed characteristics of the antibody response.
Background
Around 40% of the world's population is at risk from
malaria. Current widespread parasite drug resistance and
insect pesticide resistance call for urgent development of
new control tools, including malaria vaccines. Rationale
vaccine development is challenged by the complexity of
the life cycle and the large number of potential vaccine tar-
gets [1,2]. The search for genetic evidence of diversifying
selection has been proposed as a strategy to identify major
targets of protective immunity [3]. Several antigens under
putative immune selection have been uncovered this way
[4-7], including the N-terminal polymorphic domain of
the merozoite surface protein-1 (MSP1), called MSP1
block2 [3].
MSP1-block2 shows extensive allelic polymorphism, with
over 120 variants identified worldwide, grouped into
three families or types and one recombinant type [8-21].
In parasite populations from Africa and Southeast Asia,
Pfmsp1 block2 showed a low inter-population variance,
with a very low FST value, suggesting strong balancing
selection to maintain family types within each population
[3]. In agreement with this, in vitro inhibition of P. falci-
parum cultures by monoclonal antibodies reacting with
MSP1 block2 was family-specific [22]. Studies in humans
exposed to malaria showed that antibodies to MSP1
block2 were family-specific (also called type-specific by
some authors) [3,23-33]. The same was observed in mice
immunised with recombinant proteins derived from ref-
erence alleles from each family [27,34]. Importantly, pres-
ence of antibodies to recombinant proteins of the K1- and
MAD20 types was negatively associated with clinical
malaria in prospective studies in Gambian [3,23] and
Ghanaian children [24]. In contrast, levels of anti-MSP1
block2 IgG were positively associated with an increased
risk of subsequent reinfection and/or a lower ability to
control parasitaemia in older individuals in Mali [35].
Thus, the involvement of antibodies to MSP1 block2 in
parasite control and protection is still unclear.
The K1 and MAD20 MSP1 block 2 families are character-
ised by the presence of central three amino acids repeats.
The various K1- and MAD20-type block2 alleles differ in
the number, sequence and relative arrangement of tripep-
tide repeats and in point mutation polymorphism of the
flanking regions. The non-repetitive RO33 alleles only dif-
fer by point mutations [8]. The fourth family type called
MR, which has been identified recently, results from
recombination between the Mad20 and RO33 families
[11,16]. Within each MSP1 block2 family, multiple
sequence variants have been described.
Analysis of antibody responses in humans living in
endemic areas using up to four full length recombinant
proteins per family alongside recombinant sub-domains
such as repeats only or flanking regions expressed in
Escherichia coli [3,23-25,28,30-33,36] showed family-spe-
cific responses, with no inter-family cross-reactivity. Anti-
bodies to specific sub-types within each family were
observed as well [23,25,28,31], and their prevalence var-
ied with malaria transmission conditions [23,24,28].
Monitoring of the antigenic consequences of sequence
variation at the single epitope level was done using arrays
of synthetic peptides [15,26,27,29]. Interestingly, this
showed that sera from mice immunised with a full length
recombinant protein reacted with peptides derived from
the immunising allele but not with any of its sequence
variants [23,27]. Sequence-dependent specificity of indi-
vidual epitopes was similarly outlined using monoclonal
antibodies [15,22,37]. In African populations exposed to
P. falciparum, the response to MSP1 block2, assessed using
synthetic sequence variants displayed a restricted specifi-
city [15,26,27].
The antibody response to MSP1-block2 correlated with
PCR typing of the parasites present at the time of plasma
collection in some settings [25], weakly in some others
[3,31] and not in others [27,33]. In Senegal, fine specifi-
city of the antibodies to MSP1 block2 did not match with
the infecting type and moreover was fixed over time, with
no novel antibody specificity acquired upon cumulated
exposure to multiple infections [27]. Interpretation of
these studies has been limited insofar as molecular
sequence data and sequence-specific serological responsesBMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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were not gathered from the same population/setting [15],
or sequence data were generated without exploring the
immune response [9-14,16,17] or alternatively, immuno-
logical responses were studied without detailed knowl-
edge of the actual sequence polymorphism of the local
population [23-28,30,33]. Thus, whether the acquired
antibodies to MSP1 block2 select for parasites presenting
novel sequence variants and exert a significant diversify-
ing selection at the epitope level remains to be studied.
We set out to address this question and analysed Pfmsp1
block2 sequence polymorphism and sequence-specific
antibody responses using archived samples collected in
Dielmo, a Senegalese rural setting. We have analysed
sequence polymorphism of the locus over a 10 year
period to gain a view of its overall polymorphism and
possible temporal evolution. We have explored the
humoral response of the villagers to MSP1 block2 using
synthetic peptides displaying numerous sequence vari-
ants. Serological studies have included a cross-sectional
study to measure point prevalence at the village level
before a rainy season, a prospective study to explore the
relationship between the presence of antibodies to MSP1
block2 at enrolment and protection from clinical malaria
episodes during the following five months of intense
transmission, and longitudinal follow up of individuals
to study temporal antibody variation. This showed evi-
dence for family-specific responses possibly exerting a bal-
ancing selection, but gave no support to the notion of
antibody selection for variant sequence alleles.
Results
Pfmsp1 block2 PCR genotyping: distribution of allelic 
families
A total of 306 samples were successfully genotyped by
semi-nested PCR. Overall 524 PCR fragments were gener-
ated (Table 1). There were 247, 145 and 132 fragments
assigned to the K1, Mad20 and RO33 allelic families,
respectively. Based on fragment size polymorphism, 32
and 23 K1-type and Mad20-type alleles could be identi-
fied [see Additional file 1]. All RO33 fragments were of the
same size. The family frequencies were 47%, 28% and
25% for K1, Mad20 and RO33, respectively. The relative
proportion of the three allelic families (Figure 1) did not
show significant temporal fluctuations (Pearson test, Chi2
= 14.99; p = 0.663), was not influenced by age (Fisher's
exact test, p = 0.813), gender (idem, p = 0.45), β-globin
type (idem, p = 0.678 for AA vs. AS; p = 0.923 AA vs. AS vs.
other  β-globin variants), ABO blood group (idem  p =
0.688) or Rhesus blood group (idem p = 0. 390).
Many samples contained more than one Pfmsp1 block2
type. The average multiplicity of infection estimated from
the number of fragments detected (estimated moi - see
Methods) was 1.73 Pfmsp1 block2 fragments/sample.
This figure does most probably not reflect the actual
number of distinct clones present in the patient, as dis-
tinct Pfmsp1 block2 alleles yet of similar size are not taken
into account and as parasites with identical Pfmsp1
block2 alleles may differ in multiple other loci across their
genome.
The number of Pfmsp1  block2 fragments detected was
influenced by age (Kruskal Wallis test, p = 0.0192) (Figure
2); it was highest in the 2-5 y and 6-9 y old children and
lowest in the ≥ 20 y old. It was not associated with gender
(Kruskal Wallis test, p = 0.670), β-globin type (idem, p =
0.482), ABO or Rhesus blood group (idem, p = 0.234 and
p = 0.839, respectively) or with year of study (idem, p =
0.508).
Analysis of infection rates by individual allelic families
One or more K1-type and Mad-type 20 alleles were
detected in 73% and 44% of the samples, respectively,
while the RO33 family was observed in 43% of the
patients. For each of the three families, the infection rate
Table 1: Number of isolates studied by calendar year of survey and successfully genotyped for the Pfmsp1 block2 locus by nested PCR 
and gene sequencing
PCR genotyping Sequencing
year of survey No samples studied No samples typed No alleles detected Mean No alleles 
detected/sample
No PCR fragments 
sequenced
1990 23 23 46 2,00 27
1991 30 29 49 1,69 32
1992 30 29 43 1,48 33
1993 37 36 63 1,75 45
1994 35 34 54 1,59 37
1995 38 33 51 1,55 40
1996 46 38 68 1,79 48
1997 26 25 46 1,84 29
1998 52 44 76 1,73 51
1999 19 15 28 1,87 16BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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was not associated with gender (Fisher's exact test p =
0.164, 0.260, 0.289 for K1, Mad20 and RO33, respec-
tively), β-globin type (Fisher's exact test p = 0.498, 0.704
and 0.384 for K1, Mad20 and RO33 respectively), ABO
blood group (Fisher's exact test p = 0.195, 0.721 and
0.467 for K1, Mad20 and RO33, respectively) and Rhesus
blood groups (Fisher's exact test p = 1.000, 0.268 and
0.370 for K1, Mad20 and RO33, respectively). Seasonality
did, however, have an influence (Figure 3). The infection
rates of K1-types were higher and those of Mad20-types
lower in the November-January period (mean no. infected
bites/month ± SD = 15.42 ± 10.07) than in February-May
(idem = 10.78 ± 8.54) or June-October (idem = 31.53 ±
18.14) (Fishers' exact test p = 0.011 and p = 0.005, respec-
tively). The RO33-type infection rates tended to be lower
in February-May compared to the two other periods (Fish-
ers' exact test, p = 0.061).
Pfmsp1 sequences
Direct sequencing generated high quality sequences on
both strands for 358 fragments. The 358 sequences
obtained accounted for 58% (144 of 247), 62% (90 of
145), and 94% (124 of 132) of the amplified K1, MAD20
and RO33 fragments, respectively, with a fair temporal
distribution of sequenced fragments [see Additional file
2].
There was a large nucleotide sequence diversity, with a
total of 126 alleles. In addition to the K1, Mad 20 and
RO33 families, the fourth MR hybrid family identified
recently [11,16], was observed (Table 2). The six RO33-
type alleles (RD0-5) differed only by point mutations. In
addition to the previously reported G97D polymorphism
[9] [see Additional file 3] four novel positions were
Temporal distribution of the relative proportion of the three  allelic families in Dielmo during 1990-99 Figure 1
Temporal distribution of the relative proportion of 
the three allelic families in Dielmo during 1990-99. 
Alleles were assigned to one of three allelic families by 
nested PCR. Distribution is shown by calendar year. The 
number of samples typed each year is shown in Table 1. Col-
our symbols: black: K1-types, white: Mad20-types, grey 
RO33 types. Note that hybrid alleles were not distinguished 
from the Mad20-types and are included in the Mad20 group.
Estimated multiplicity of infection by age group Figure 2
Estimated multiplicity of infection by age group. Esti-
mated multiplicity of infection (i.e. the mean number of 
Pfmsp1 block 2-alleles detected per sample) was calculated 
from PCR fragments generated in the nested PCR reaction. 
There were 51, 83, 61, 60 and 51 samples in the 0-1 y, 2-5 y, 
6-9 y, 10-19 y and ≥20 y age groups, respectively. The figures 
shown are the mean and SD.
Influence of seasonality on Pfmsp1 block 2 family infection  rates Figure 3
Influence of seasonality on Pfmsp1 block 2 family 
infection rates. Data from individual years were pooled. 
Three seasons were defined as February-May (yellow), June-
October (green) and November-January (hatched grey).BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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Table 2: Nucleotide sequence diversity of the 126 Pfmsp1 block2 alleles detected in Dielmo, Senegal.
code AA repeat nucleotide sequence
K1 family
1 SGT AGT GGT ACA
2 SGP AGT GGT CCA
3 SAQ AGT GCT CAA
4 SGA AGT GGT GCA
7 SVT AGT GTT ACA
MAD20 family
5 SGG TCA GGT GGT
5 SGG TCA GGT GGC
6 SVA TCA GTT GCT
7 SVT TCA GTT ACT
8 SKG TCA AAG GGT
9 SSG TCA AGT GGT
Allele Repeat motifs 24 AA family-specific region
K1 family Group1 DK1 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 2 3 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 3 3 1 1 1 1 1 1 1 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 4 3 1 1 1 1 1 1 1 1 1 1 1 3 1 3 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 5 3 1 1 1 1 1 1 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 6 3 1 1 1 1 1 1 1 1 1 1 3 1 3 1 3 1 1 1 1 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 7 3 1 1 1 1 1 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 8 3 1 1 1 1 1 1 1 2 2 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 9 3 1 1 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 10 3 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 11 3 1 1 1 1 3 1 3 1 3 1 1 1 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 12 3 1 1 1 1 3 1 3 1 3 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 13 3 1 1 1 1 3 1 3 1 3 1 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 14 3 1 1 1 2 1 2 1 2 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 15 3 1 1 1 2 1 2 1 2 1 2 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 16 3 1 1 1 3 1 1 1 3 1 1 1 3 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 17 3 1 1 1 3 1 1 3 1 1 3 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 18 3 1 1 2 1 2 1 2 1 2 1 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 19 3 1 1 2 1 2 1 2 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 20 3 1 1 2 1 2 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 21 3 1 2 1 2 1 2 1 1 1 1 2 2 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 22 3 1 2 1 2 1 2 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 23 3 1 2 1 2 1 2 1 2 2 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 24 3 1 2 1 2 1 2 1 2 2 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 25 3 1 2 1 2 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 26 3 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 27 3 1 3 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 28 3 3 1 1 1 1 1 1 1 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
K1 family Group2 DK 29 3 4 3 1 1 1 1 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 30 3 4 3 1 1 1 1 1 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 31 3 4 3 1 1 1 1 1 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 32 3 4 3 1 1 1 1 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 33 3 4 3 1 1 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 34 3 4 3 1 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 35 3 4 3 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 36 3 4 3 1 1 1 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 37 3 4 3 1 1 1 2 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 38 3 4 3 1 2 1 2 1 2 1 2 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 39 3 4 3 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 40 3 4 3 1 2 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 41 3 4 3 1 3 1 2 2 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADABMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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DK 42 3 4 3 1 3 1 3 1 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 43 3 4 3 1 3 1 3 1 1 1 1 1 1 1 1 1 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 44 3 4 3 1 3 1 3 1 1 1 1 1 1 2 1 1 2 1 SPSSRSNTLPRSNT LSGASPPADA
DK 45 3 4 3 1 3 1 3 1 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 46 3 4 3 1 3 1 3 1 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 47 3 4 3 1 3 1 3 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 48 3 4 3 1 3 1 3 1 1 2 1 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 49 3 4 3 1 3 4 3 4 3 4 3 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 50 3 4 3 1 7 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 51 3 4 3 4 3 1 1 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 52 3 4 3 4 3 1 1 1 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 53 3 4 3 4 3 1 1 1 1 1 1 1 1 1 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 54 3 4 3 4 3 1 1 1 2 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 55 3 4 3 4 3 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 56 3 4 3 4 3 1 1 3 4 3 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 57 3 4 3 4 3 1 2 1 SPSSRSNTLPRSNT LSGASPPADA
DK 58 3 4 3 4 3 1 2 1 2 1 2 2 2 1 2 2 2 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 59 3 4 3 4 3 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 60 3 4 3 4 3 1 2 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 61 3 4 3 4 3 1 3 1 3 1 3 1 3 1 SPSSRSNTLPRSNTSSGASPPADA
DK 62 3 4 3 4 3 4 3 1 1 1 1 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 63 3 4 3 4 3 4 3 1 1 1 1 1 1 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 64 3 4 3 4 3 4 3 1 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 65 3 4 3 4 3 4 3 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 66 3 4 3 4 3 4 3 1 2 2 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 67 3 4 3 4 3 4 3 1 3 1 1 1 1 1 2 1 SPSSRSNTLPRSNT LSGASPPADASPPADA
DK 68 3 4 3 4 3 4 3 4 3 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 69 3 4 3 4 3 4 3 4 3 1 1 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 70 3 4 3 4 3 4 3 4 3 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 71 3 4 3 4 3 4 3 4 3 1 2 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 72 3 4 3 4 3 4 3 4 3 1 3 1 1 1 1 1 SPSSRSNTLPRSNTSSGASPPADA
DK 73 3 4 3 4 3 4 3 4 3 1 3 1 1 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 74 3 4 3 4 3 4 3 4 3 4 3 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 75 3 4 3 4 3 4 3 4 3 4 3 1 7 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 76 3 4 3 4 3 4 3 4 3 4 3 4 3 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
DK 77 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 1 2 2 1 SPSSRSNTLPRSNTSSGASPPADA
Allele repeat motifs 13 AA family-specific region
MAD20 family Group1 DM1 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 SG -----------------NS
DM 2 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 SG -----------------NS
DM 3 5 6 5 5 6 5 5 6 5 SG -----------------NS
DM 4 5 6 5 6 5 6 5 6 5 SGNSRRTNPSDNS
DM 5 5 6 5 6 5 6 5 SGNSRRTNPSDNS
DM 6 5 7 5 5 5 6 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 7 5 7 5 5 6 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 8 5 7 5 5 5 6 5 6 5 5 6 5 SGNSRRTNPSDNS
MAD20 family Group2 DM 9 8 5 SGNSRRTNPSDNS
DM 10 8 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 5 6 5 SGNSRRTNPSDNS
DM 11 8 5 6 5 5 6 5 5 6 5 5 6 5 6 5 6 5 SGNSRRTNPSDNS
DM 12 8 5 6 5 5 5 6 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 13 8 5 6 5 5 6 5 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 14 8 5 6 6 5 6 5 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 15 8 5 6 5 5 6 6 5 6 6 5 6 5 SGNSRRTNPSDNS
DM 16 8 6 5 5 6 5 6 5 5 6 5 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 17 8 6 5 6 5 6 5 5 5 6 5 6 5 6 5 6 5 SGNSRRTNPSDNS
DM 18 8 6 5 6 5 6 5 6 5 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 19 8 6 5 6 5 5 5 6 5 6 5 6 5 6 5 SGNSRRTNPSDNS
DM 20 8 6 5 6 5 6 5 5 5 6 5 6 5 6 5 SGNSRRTNPSDNS
DM 21 8 6 5 6 5 6 5 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 22 8 6 5 6 5 5 5 6 5 6 5 6 5 SGNSRRTNPSDNS
Table 2: Nucleotide sequence diversity of the 126 Pfmsp1 block2 alleles detected in Dielmo, Senegal. (Continued)BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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dimorphic (Q72E, K90N, G91D and D104N). The K1
family presented the highest diversity, with 77 distinct K1
alleles (DK1-77). Sequencing of 90 fragments assessed by
nested PCR to the Mad20 resulted in identifying only 34
distinct Mad20-type alleles (DM1-34) and nine hybrid
types (DMR1-8, and DMRK).
The K1- Mad20- and hybrid-types mainly differed in copy
number and arrangement of sequence motifs called in the
literature "tripeptide motifs", while presenting no or min-
imal polymorphism of the flanking family-specific
sequence. Five distinct tripeptide motifs were observed in
the K1 types. In addition to the known SGT, SGP, SAQ
and SGA motifs (coded 1-4, respectively according to
[9,12]), a novel motif was observed (motif 7 in Table 2),
which encodes the SVT tripeptide sequence displayed so
far only by Mad20 types. Motif 7 presented a typical K1-
type signature, with AGT coding for Ser, as opposed to a
TCA/G codon in the Mad20 types. All K1-type alleles con-
tained more than one motif sequence, resulting in eleven
di-motif combinations (hexapeptides). Most alleles had
three or four different motifs (Figure 4A). Some di-motifs
were very frequent and motif 3 1 was present in all alleles
[see Additional file 4]. A clear dichotomy could be delin-
eated based on the first 5' di-motif being either 3 1 (group
1, 28 alleles) or 3 4 (group 2, 49 alleles) (with the excep-
tion of allele 28 which displayed a 3 3 motif). Limited pol-
ymorphism was observed in the 3' family-specific region,
with a non-synonymous S to L (tca>tta) mutation,
observed in three alleles, and a six amino acid insertion,
SPPADA, observed in a single allele (Table 2).
Similar findings were observed for the Mad20 types alle-
les, which differed mainly in the number, arrangement
and coding sequence of six tripeptide motifs (coded 5-9).
There were two synonymous sequences coding for SGG (5
and 5) such that all Mad20-type alleles contained an SGG-
encoding motif [see Additional file 4]. In this family too,
all alleles contained more than one motif sequence. The
majority had four distinct nucleotide sequence motifs
DM 23 8 6 5 6 5 5 6 5 5 6 5 5 6 5 SGNSRRTNPSDNS
DM 24 8 6 5 5 6 5 5 6 5 6 5 6 5 SGNSRRTNPSDNS
DM 25 8 6 5 6 5 6 5 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 26 8 6 5 5 5 6 5 6 5 6 5 SGNSRRTNPSDNS
DM 27 8 6 5 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 28 8 6 5 6 5 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 29 8 6 9 6 5 SGNSRRTNPSDNS
DM 30 8 7 5 5 5 6 5 5 6 5 5 5 6 5 6 5 6 5 SGNSRRTNPSDNS
DM 31 8 7 5 5 5 5 6 5 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 32 8 7 5 5 5 6 5 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
DM 33 8 7 5 5 5 6 5 6 5 6 5 6 5 6 5 SGNSRRTNPSDNS
DM 34 8 7 5 5 6 5 5 6 5 5 6 5 6 5 SGNSRRTNPSDNS
RO33-family mutation sequence
RD0 KPADAVSTQSAKNPPGATVPSGTASTKGAIRSPGAANPSDDS
RD1 Q72E KPADAVSTESAKNPPGATVPSGTASTKGAIRSPGAANPSDDS
RD2 K90N KPADAVSTQSAKNPPGATVPSGTASTNGAIRSPGAANPSDDS
RD3 G91D KPADAVSTQSAKNPPGATVPSGTASTKDAIRSPGAANPSDDS
RD4 G97D KPADAVSTQSAKNPPGATVPSGTASTKGAIRSPDAANPSDDS
RD5 G97D/D104N KPADAVSTQSAKNPPGATVPSGTASTKGAIRSPDAANPSDNS
Hybrids Allele MAD20 repeat motif C-terminal specific region
DMR1 5 7 5 5 4 TVPSGTASTKGAIRSPDAANPSDNS
DMR 2 8 7 5 4 TVPSGTASTKGAIRSPDAANPSDNS
DMR 3 8 7 5 5 4 TVPSGTASTKGAIRSPDAANPSDNS
DMR 4 8 7 5 5 5 4 TVPSGTASTKGAIRSPDAANPSDNS
DMR 5 8 7 5 5 5 6 4 TVPSGTASTKGAIRSPDAANPSDNS
DMR 6 8 7 5 5 5 5 4 TVPSGTASTKGAIRSPDAANPSDNS
DMR 7 8 7 5 5 5 5 5 4 TVPSGTASTKGAIRSPDAANPSDNS
DMR 8 8 7 5 5 5 5 5 5 4 TVPSGTASTKGAIRSPDAANPSDNS
DMRK 8 7 5 5 5 5 4 TVPSGTASTKGAIRSPDAASPPADA
Codes for K1- and Mad20-types tripeptide repeats together with the nucleotide sequence are as proposed in [9,12]. Sequence of the K1-type 
alleles are grouped as mentioned in the text based on the 5' di-motif and the presence of motif 4 and 7. Sequence of the Mad20-type alleles are 
grouped as mentioned in the text based on the 5' motifs.
Table 2: Nucleotide sequence diversity of the 126 Pfmsp1 block2 alleles detected in Dielmo, Senegal. (Continued)BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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(Figure 4B), encoding three different tripeptide sequences
(Figure 4C). Some di-motifs were highly represented, with
the SVA SGG motif (6 5 or 6 5) being present in virtually
all alleles. There was a dichotomy within the family based
on the first 5' motif, being either 5/5 (group 1, 8 alleles)
or 8 (group 2, 26 alleles) (Table 2). This group-specific 5'
Distribution of Pfmsp1 block2 allele frequency in Dielmo Figure 5
Distribution of Pfmsp1 block2 allele frequency in 
Dielmo. A. Distribution by family based on sequenced alle-
les: K1-types (N sequenced = 144), Mad20-types grouped 
together with hybrid types (N sequenced = 90) and RO33-
types (N sequenced = 124). Each family is depicted sepa-
rately, with alleles ranked clockwise by allele number coded 
as shown in Table 2. B. Relative individual allele frequency in 
the 358 sequenced fragments (top) and adjusted to the over-
all population based on relative family distribution established 
by nested PCR on 524 PCR fragments (bottom). Identical 
colour codes used for A and B, ordered clockwise as follows: 
RD types (light blue colours), Hybrids (green and orange), 
DM (orange-yellow) and DK alleles (indigo-dark blue col-
ours), with alleles ranked clockwise by allele number coded 
as shown in Table 2.
Frequency distribution of the number of tri-peptide motif  usage in the DK and DM alleles Figure 4
Frequency distribution of the number of tri-peptide 
motif usage in the DK and DM alleles. A: Frequency dis-
tribution of K1-type alleles (DK alleles) by number of distinct 
tripeptides present. B. Frequency distribution of Mad20-
types (DM alleles) by number of distinct tripeptide nucle-
otide sequences present (DMR, DMRK and MK hybrids 
excluded). C. Frequency distribution of Mad20-types DM 
alleles (by number of distinct tripeptide protein sequences 
present (DMR, DMRK and MK hybrids excluded).BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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Table 3: Ewens-Watterson (EW) tests for neutrality for Pfmsp1 block2 alleles from Dielmo, Senegal.
Year Sample size Observed F Expected F p-values
1990 46 0.3535 0.626 0.0201
1991 49 0.3536 0.6302 0.021
1992 43 0.3618 0.6213 0.0317
1993 63 0.3923 0.6463 0.0584
1994 54 0.3957 0.6366 0.0662
1995 51 0.4048 0.633 0.08
1996 68 0.3387 0.651 0.0051
1997 46 0.3573 0.626 0.0253
1998 76 0.3695 0.6575 0.0303
1999 28 0.398 0.5894 0.099
All 524 0.3622 0.7429 0.0108
Size polymorphism Size and sequence polymorphism
Year N Observed F Expected F p-value N Observed F Expected F p-value
K1 family
1990 18 0.1728 0.17 0.6612 8 0.1562 0.1562 1
1991 22 0.095 0.099 0.577 11 0.157 0.1542 0.8934
1992 20 0.195 0.1789 0.7793 14 0.0816 0.0816 1
1993 33 0.0964 0.1379 0.0186 20 0.065 0.0607 1
1994 29 0.1249 0.1294 0.551 15 0.0756 0.0756 1
1995 28 0.148 0.1422 0.6971 18 0.1111 0.1113 0.6803
1996 26 0.1775 0.1757 0.6323 18 0.0988 0.1113 0.267
1997 20 0.245 0.1551 0.9901 11 0.0909 0.0909 1
1998 37 0.122 0.1316 0.4808 21 0.1111 0.0962 0.936
1999 14 0.1939 0.2125 0.417 8 0.125 0.125 1
All 247 0.1044 0.0957 0.7197 144 0.0245 0.0214 0.9088
MAD20 family + Hybrid alleles
1990 18 0.1358 0.1273 0.8024 9 0.1605 0.1683 0.6858
1991 13 0.2071 0.2505 0.2629 8 0.1562 0.1562 1
1992 13 0.1834 0.1698 0.8471 9 0.1111 0.1111 1
1993 18 0.1728 0.1995 0.3267 13 0.1243 0.1208 0.9238
1994 12 0.1667 0.1973 0.2356 9 0.1358 0.1358 1
1995 10 0.32 0.2831 0.9022 9 0.1605 0.1683 0.6858
1996 23 0.2098 0.1906 0.7541 12 0.0972 0.0972 1
1997 16 0.1797 0.1886 0.5808 11 0.1736 0.1885 0.5419
1998 18 0.2037 0.2369 0.3518 10 0.14 0.1455 0.7227
1999 4 0.25 0.25 1 NA NA NA NA
All 145 0.1177 0.1201 0.5816 90 0.0365 0.0407 0.2691
RO33 family
1990 NA NA NA NA 10 0.66 0.4919 1
1991 NA NA NA NA 13 0.7396 0.7035 0.6469
1992 NA NA NA NA 10 0.68 0.6826 0.6047
1993 NA NA NA NA 12 0.8472 0.6975 1
1994 NA NA NA NA 13 0.3609 0.3976 0.3849
1995 NA NA NA NA 12 0.7222 0.6975 0.6347
1996 NA NA NA NA 18 NA NA NA
1997 NA NA NA NA 9 0.358 0.4797 0.1481
1998 NA NA NA NA 20 0.745 0.7331 0.5446
1999 NA NA NA NA 7 0.5102 0.6509 0.2358
All NA NA NA NA 124 0.6403 0.4419 0.8793
Ewens-Watterson tests by individual year during the 1990-1999 decade and for all years of the decade grouped together (All). In the top Table, tests 
were based on family frequency distribution. Three families were considered: K1, MAD20/Hybrids and RO33. The second part shows the results of 
the Ewens-Watterson tests within each family with alleles identified by size polymorphism only or both size and sequence polymorphism. For the 
RO33 family no size polymorphism was observed.
F: Homozygosity. N: sample size. NA: Not Available.BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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end was followed by a variable copy number and arrange-
ment of six di-motif sequences, which at the protein level
translated into variable combinations of the SGG and SVA
tripeptides. All Mad20-type block2 repeats except two
(DM9 and DM29) terminated with the (5 6 5) sequence.
The flanking non repeated region upstream from the
tripeptide motifs was identical in all alleles. Downstream
from the repeats, a 9 amino acid deletion (NSRRTNPSD)
was observed in three alleles, but otherwise the family-
specific region was monomorphic.
Sequencing showed that 22 fragments assigned to the
Mad20 family by semi-nested PCR were indeed Mad20/
RO33 (MR) hybrids. We are confident that these alleles
are bona fide hybrids and not artifactual PCR products, as
they have been observed in 14 of 22 samples where a
RO33 allele could not be detected using multiple family-
specific nested PCR reactions. Moreover, 7 of 22 samples
where the MR allele was detected by sequencing were
monoinfections (i.e. there were no two partners for tem-
plate switching). This MR hybrid family was quite diverse
as eight alleles were observed. Allele DMR1 had a group1
type Mad20 while alleles DMR 2-8 derived from Mad20
group 2. All DMR alleles carried the same 25-residue long,
RO33-type downstream region, which interestingly was a
RD5 allelic type with a G97D D104N double mutation
(Table 2). A novel hybrid, DMRK, displayed a RO33-K1
hybrid sequence in the family-specific 3' region (the K1
sequence located in 3' is underlined in Table 2) [for fur-
ther analysis see Additional file 4].
The large local diversity was associated with a large
number of low frequency alleles in the K1 and Mad20/MR
family types, contrasting with the RO33 family where a
dominant RD0 allele was observed in 78% (97 of 124) of
the sequenced RO33-types alleles (Figure 5A). At the pop-
ulation level (Figure 5B), RD0 was by far the most fre-
quent allele, accounting for 27% of the sequenced
samples (top pie chart) and 19.7% of all alleles within the
village when adjusted for relative family frequency esti-
mated by nested PCR genotyping (bottom pie chart). The
second most frequent allele after adjusting for family fre-
quency was DK65 (adjusted frequency: 4.6%). Most alle-
les (107 of 126) presented a less than 1% frequency in the
population sample studied here. In terms of frequency,
the largest contribution among the top 19 alleles came
from the RO33 family.
Sequence comparison of Dielmo alleles with the RO33-,
K1-, Mad20-, and MR-types alleles deposited in the data-
base [see Additional file 3], [see Additional file 5], [see
Additional file 6], [see Additional file 7], respectively,
Table 4: Neutrality tests for the RO33 family in Dielmo, Senegal
nucleotide position amino acid position
allele mutation N 197 199 200 214 270 272 290 310 66 67 72 90 91 97 104
RD0 R033 97 C G A C A G G G A D Q K G G D
RD1 Q72E 1 . . . G . . . . . . E . . . .
R D 2 K 9 0 N 5 ....T... . . . N . . .
RD3 Q91D 4 . . . . . A . . . . . . D . .
R D 4 G 9 7 D 2 ...... A . . .... D.
R D 5 G 9 7 D  D 1 0 4 N 1 5 ...... A A . .... D N
Year n h S Ss (π × 10-3) Tajima's D
(P-value)
Fu and Li's D*
(P-value)
Fu and Li's F*
(P-value)
1990 10 3 2 2 3.17 -1.4009 (>0.1) -1.5866 (>0.1) -1.7190 (>0.1)
1991 13 2 1 0 2.24 - 0.27429 (>0.1) 0.73235 (>0.1) 0.54307 (>0.1)
1992 10 2 2 0 7.41 1.03299 (>0.1) 1.02623 (>0.1) 1.14601 (>0.1)
1993 12 2 2 2 2.65 -1.45138 (>0.1) -1.72038 (>0.1) 1.86451 (>0.1)
1994 13 4 4 0 8.95 -0.42367 (>0.1) 1.17832 (>0.1) 0.86962 (>0.1)
1995 12 2 1 0 2.41 -0.19492 (>0.1) 0.75202 (>0.1) 0.58317 (>0.1)
1996 18 1 0 0 0 - - -
1997 9 3 2 0 8.38 1.49448 (>0.1) 1.06300 (>0.1) 1.28730 (>0.1)
1998 20 2 2 0 4.26 -0.11187 (>0.1) 0.86615 (>0.1) 0.69109 (>0.1)
1999 7 2 2 0 9.07 1.64955 (>0.1) 1.17810 (>0.1) 1.37408 (>0.1)
All 124 6 5 1 4.84 -07033 (>0.1) -0.0713 (>0.1) -0.3316 (>0.1)
Sequence diversity is shown in the upper half of the Table with the nucleotide sequence on the left and the amino acid sequence in single letter 
code on the right. N: number of isolates.
The lower half of the Table shows the sequence diversity tests by year and all years combined (All)
n: number of samples; h: number of haplotypes; S: number of segregating sites; Ss: number of singleton sites; π: average nucleotide diversity. Tajima's 
and Fu and Li's tests were implemented by the DnaSP version 4 software, and validated by Fisher's exact tests.BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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showed that only 13 of the 126 alleles from Dielmo were
identical to reported sequences from other endemic set-
tings, namely K1-types (DK5, -7, -9, -18, -59, -65 -70 and
-74), two Mad20-types (DM29 and DM34), two RO-33
types (RD0 corresponding to RO33-Ghana and RD4) and
one MR allele (DMR4) [see Additional file 8]. Interest-
ingly, only four of the top 19 alleles have been reported
elsewhere in the world, (DK59, DK65, DMR4 and RD0),
suggesting local diversification of the parasite population.
Tests for neutrality
To gain some insight into a possible positive selection on
this locus regarding the level (family and/or intra-family)
and the type of selection operating, Ewens-Watterson-
Slatkin tests for neutrality [38,39] were conducted. At the
family level, i.e. grouping alleles by family type consider-
ing three families irrespective of size or sequence poly-
morphism, this showed a significant departure from
neutrality on a yearly basis and when grouping all years
together, i.e. for a 10 year period (Table 3). Thus, there
was evidence for balancing selection at the family level in
this setting, the observed homozygosity being lower than
expected (Table 3).
We then considered the within family diversity of the K1,
Mad20/Hybrids (DMR and DMRK) and RO33 alleles sep-
arately to look for evidence of selection within each family
(Table 3 lower panels). Tests were performed for each year
separately or for the 10 year period. Alleles were differen-
tiated by either size polymorphism or both size and
sequence polymorphism. Overall, the null hypothesis was
not rejected, implying that there was no evidence for sig-
nificant within-family balancing selection on the Pfmsp1
block2 locus. The results of these Ewens-Watterson-Slat-
kin tests need to be interpreted with caution though.
These tests are based on the assumption that no recurrent
mutation has occurred at the locus studied. Since the
mutation rate is known to be high in minisatellite/repeti-
tive sequences, this assumption may be violated. In other
words, one cannot exclude that recurrent mutations may
have occurred and in turn have artificially reduced our
power to detect balancing selection acting at the intra-
family level.
Within the 124 RO33 PCR fragments sampled there was
no size polymorphism and six different allele sequences
were identified. An alignment of 126 nucleotides for all
124 alleles contained five polymorphic sites, all of which
were non-synonymous single nucleotide polymorphisms.
This indicates that dN/dS is infinite. Nucleotide diversity
(π = average number of differences between any two
sequences) was 4.84 × 10-3. To examine the possibility of
natural selection acting on the RO33 family, Tajima's D
and Fu and Li's D* and F* were calculated [40,41]. In view
of the high number of segregating sites (N = 5), these tests
are expected to show high statistical power for natural
selection. No evidence for departure from neutrality was
obtained, with non significant Tajima's D value, Fu and
Li's D* and F* values (Table 4), thus confirming results
obtained using the Ewens-Watterson test.
Anti-MSP1 block2 antibody prevalence and specificity
The sequence-specific antibody response was studied by
ELISA using biotinylated MSP1 block2-derived peptides
bound to streptavidin-coated plates that overall repre-
sented a fair coverage of the sequence diversity observed
in the village [see Additional file 9]. We recorded as sero-
positive any individual reacting with one or more peptide.
Seroprevalence was analysed at the village level using an
archived cross-sectional study conducted at the beginning
of the 1998 rainy season, to which 85% of the villagers
had contributed. We recorded as seropositive any individ-
ual reacting with one or more peptide. Overall, seroprev-
alence was 25% (62 of 243 sera analysed). Seroprevalence
increased with age and reached 40.5% in adults (Figure
6). Confirming previous observations in this setting
[26,27], all anti-block2 IgGs were exclusively IgG3 [see
Additional file 10]. No anti-block2 IgM was detected.
The frequency of recognition of each allelic family mir-
rored the frequency distribution of the family types within
the parasite population (Figure 7A). The antibody reac-
Prevalence of anti-MSP1-block 2 IgG by age group Figure 6
Prevalence of anti-MSP1-block 2 IgG by age group. 
Seroprevalence was determined using sera collected during a 
cross-sectional survey conducted before the 1998 rainy sea-
son (on 2-3 August 1998) when 243 villagers (i.e. 95% of the 
village population) donated a fingerprick blood sample. The 
presence of anti-MSP1 block2 specific IgG was assessed by 
ELISA on 16 pools of biotinylated peptides (sequence and 
composition of the pools described in Table 5). Plasma react-
ing with one or more pool was considered seropositive. 
Number of individuals by age group: 27, 25, 26, 40, 46 and 79 
in the 0-2, 3-5, 6-8, 9-14, 15-24, ≥ 25 year group, respec-
tively.B
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Table 5: Composition of the 16 pools of MSP-1 derived peptides.
Pool Localisation Peptide sequence
P1 Block 1 Mad20 01 
TGYSLFQKEKMVLNE
60 
TGYGLFQKEKMVLNE
45 
TGYSLFHKEKMILNE
45 
TGYSLFHKEKMILNE
73 
TGYGLFHKEKMLLNE
P2 Block 3 10 
RTNPSDNSSDSDAKS
27 
RTNPSDNSSDSNTKT
28 
SSDSNTKTYADLKHR
40 
GAANPSDDSSDSDAK
72 
DASDSDAKSYADLKH
P3 N-term MAD20 02 
KEKMVLNEGTSGTAV
03 
EGTSGTAVTTSTPGS
13 
VTTSTPGSKGSVASS
04 
VTTSTPGSGGSVTSG
29 
VTTSTPGSSGSVASG
P4 N-term MAD20 11 
VTTSTPGSSGSVTSG
25 
VTTSTPGSKGSVTSG
14 
SKGSVASSGSVASGG
05 
SGGSVTSGGSGGSVA
P5 Central MAD20 16 
SGGSVTSGGSVTSGG
17 
GGSVTSGGSGASVAS
26 
SSGSVTSGGSVASVA
30 
SSGSVASGGSVASVA
22 
GSVTSVASVASVASV
P6 Central MAD20 15 
GGSGGSVASGGSVAS
18 
GSGASVASVASVASV
32 
SVASGGSVASGGSGN
23 
SVASVASVASVASGG
07 
ASVASGGSGGSVASG
P7 C-term MAD20 06 
GGSGGSVASVASGGS
31 
GGSVASVASGGSGGS
19 
SVASVASVASGGSGN
08 
SGGSVASGGSGNSRR
12 
ASVASGASGGSGNSR
P8 C-term MAD20 24 
VASVASGGSGNSRRT
20 
VASGGSGNSRRTNPS
09 
GGSGNSRRTNPSDNS
21 
NSRRTNPSDNSSDSD
P9 N-term RO33 33 
KEKMVLKDGANTQVV
34 
DGANTQVVAKPADAV
41 
DGANTQVVAKPVPAV
43 
DGANTQVVAKPAGAV
35 
VAKPADAVSTQSAKN
P10 C-term RO33 42 
VAKPVPAVSTQSAKN
44 
VAKPAGAVSTQSAKN
36 
VSTQSAKNPPGATVP
37 
NPPGATVPSGTASTK
38 
PSGTASTKGAIRSPG
39 
KGAIRSPGAANPSDD
P11 N-term K1 46 
KEKMILNEEEITTKG
61 
KEKMVLNEEEITTKG
74 
KEKMLLNEEEITTKG
47 
EEEITTKGASAQSGT
76 
EEEITTKGASAQGSS
P12 N-term K1 48 
GASAQSGTSGTSGTS
62 
GASAQSGASAQSGAS
77 
GASAQGSSGPSGTPS
56 
TSGTSGTSGTSGTSG
49 
TSGTSGTSGPSGPSG
P13 Central K1 67 
TSGTSGPSGPSGTSP
75 
TSGTSGPSGTSPSSR
57 
GTSGTSAQSGTSGTS
65 
GTSAPSGSGTSPSSR
80 
GTSGPSGTGPSGTSP
P14 Central K1 79 
SGTSGPSGTSGPSGT
50 
SGPSGPSGTSPSSRS
68 
SGPSGTSPSSRSNTL
78 
SGPSGTPSGTSGPSG
58 
SAQSGTSGTSAQSGT
64 
SAQSGPSGTSAPSGS
P15 C-term K1 63 
QSGASATSAQSGPSG
59 
TSGTSGTSGTSPSSR
51 
GTSPSSRSNTLPRSN
69 
PSSRSNTLPRSNTSS
52 
SNTLPRSNTSSGASP
81 
LPRSNTSSGASPPAD
P16 C-term K1 70 
LPRSNTSSGAIPPAD
66 
SNTSSGAPPADASDS
53 
NTSSGASPPADASDS
71 
SGAIPPADASDSDAK
82 
SGASPPADASDSDAK
54 
PPADASDSDAKSYAD
The 15-mer peptide sequence is represented in single letter code, and the location of the peptide in the region is indicated. Pools contained equimolar amounts of four to six biotinylated peptides 
(0.1 nM each).BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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tion was family-specific and usually restricted to one fam-
ily, with 73%, 23% and only 4% of the positive plasma
reacting with one, two and three allelic families, respec-
tively (Figure 7B), consistent with our previous survey in
this village [27]. Figure 7C shows that antibody response
to pools 1 and 2, derived from the adjacent block 1
domain and block 3 respectively, was rare. No immuno-
dominant region was identified within block2. Antibod-
ies to the repeats were detected alongside antibodies to
the family-specific N- or C-terminus block2 sequences.
Interestingly, when scrutinizing the response at the indi-
vidual peptide level in the context of the allelic sequence
diversity within this village, it was clear that antibodies
reacted with motifs displayed by the vast majority of the
alleles observed in the village, namely either frequent/uni-
versal di-motifs (such as motif 31 in the K1 family) or
family-specific unique sequences. Indeed, 24 of 26 villag-
ers with antibodies to K1-type peptides reacted with
sequences present in 74 or more of the 77 observed K1
alleles. Similarly, 16 of 16 responders to Mad20-type pep-
tides reacted to sequences present in 32 or more of the 34
observed alleles.
In addition to the family-specific antibodies, some villag-
ers had sequence-variant specific antibodies, namely
reacted with only one of sibling peptides while others
reacted with multiple sibling peptides displaying
sequence variants. For example, within the group of sib-
ling peptides derived from the N-terminus of Mad20
block2 (peptides #04, 13, 25, 11 and 29), some villagers
reacted with one peptide (#29), whilst others reacted with
two (#29 and 04 or 29 or 11), but none reacted with all
five peptides. Likewise for the group of sibling peptides
derived from the K1 block1/block2 junction (peptides
#46, 61 and 74), some villagers reacted with one (#61),
two (#61 and 74) or all three peptides. This suggests that
sequence variation indeed translates into antigenic poly-
morphism. Whether antibody reaction with multiple
sequence variants reflects serologic cross-reaction or accu-
mulation of distinct antibody specificities is unclear.
Antibodies to MSP1 block2 and subsequent clinical 
malaria
To look for a putative association between the presence of
anti-MSP1 block2 antibodies and protection against clin-
ical malaria during the subsequent high transmission sea-
son, we mined the database for the occurrence of clinical
attacks within the 5-month period following the 1998
cross-sectional blood sampling studied above. The 243
individuals experienced a total of 266 clinical malaria
attacks (mean = 1.09, 95%CI: 0.88-1.30). The number of
clinical malaria attacks experienced per individual varied
from 0 (140 individuals) to 7 (1 individual). Recordings
of the entomological inoculation rate indicated a mean of
Seroprevalence and specificity of anti-MSP1-block 2 IgG in  Dielmo Figure 7
Seroprevalence and specificity of anti-MSP1-block 2 
IgG in Dielmo. A) Seroprevalence to each family and family 
distribution within the parasite population. Seroprevalence 
was determined using sera collected during a cross-sectional 
survey conducted before the 1998 rainy season (on 2-3 
August 1998) when 243 villagers (i.e. 95% of the village popu-
lation) donated a fingerprick blood sample. The presence of 
anti-MSP1 block2 specific IgG was assessed by ELISA on 16 
pools of biotinylated peptides (sequence and composition of 
the pools described in Table 5). Plasma reacting with one or 
more pool was considered seropositive, and grouped by fam-
ily irrespective of the number of peptides sequences recog-
nised within each of the three family types (i.e. MR alleles 
were disregarded as such, seropositivity being allocated 
either to Mad20 or to RO33). The relative distribution of 
family genotypes was established by nested PCR on 306 sam-
ples collected longitudinally during the 1990-9 time period as 
shown in Table 1. Colour codes K1: dark blue; Mad20: 
orange, RO33: light blue. B) Frequency of plasma with anti-
bodies reacting with one, two and three allelic families. The 
number of families recognised is shown irrespective of the 
actual type recognised (i.e. individuals reacting with only K1-
types, only Mad20-types or only RO33-types are placed 
together in the group reacting with one family). C) Fre-
quency of reaction with each peptide pool.BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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170 infected bites/person during this time period.
Twenty-nine percent of the seronegative individuals (with
no detected anti-MSP1 block2 antibodies) experienced a
clinical attack during that period, compared with 15% of
individuals with anti-block2 antibodies. Using a Poisson
regression model, the crude estimates of the Incidence
Rate Ratio (IRR) of malaria attacks associated with the
presence of antibodies to one allelic family or ≥ 2 families
(no antibodies as reference group) were 0.55 (95%CI:
0.38-0.80) and 0.21 (95%CI: 0.08-0.58), respectively (P <
0.0001). In a multivariate Poisson regression analysis, this
association was independent of haemoglobin type or eth-
nic group. However, it was confounded by age, i.e. within
the age groups, there was no significant association
between the incidence of clinical malaria attacks and the
number of MSP1 block2 allelic families recognized.
Analysis of the response during a high transmission season
To study the impact of novel infections during the trans-
mission season on the humoral response to MSP1 block2,
we investigated the fingerprick blood samples collected
from 25 seropositive individuals throughout the high
transmission season.
By the end of December 1998, namely five months after
the cross-sectional sampling, the anti-MSP1 block2 anti-
body level was reduced by ≥ 2-fold in 15 subjects (59%),
had varied less than 2-fold in 9 individuals (36%) (typical
profiles are shown in Figure 8 upper and middle panel,
respectively) and was ≥ 2-fold higher in one individual
(Figure 8, lower panel). Importantly, when a change was
observed, it concerned the intensity of the reaction but
not its specificity. In other words, responding individuals
usually reacted with the same pool(s) and within the
pool(s) with the same individual peptide(s) before and
after the transmission season. In none of the studied indi-
viduals were novel antibody specificities stably acquired
during that time period, despite an elevated infection rate.
We then carried out a follow up of the antibody responses
in villagers who experienced clinical malaria during the 5-
month transmission season, using archived fingerprick
sera collected monthly, and when available, sera on the
day of the clinical malaria episode. Transient fluctuations
were observed, with in some cases boosting of a pre-exist-
ing response (see a representative example in Figure 9A),
in others a decrease in antibodies (idem Figure 9B) or evi-
dence of a short-lived response (idem Figure 9C). This was
also observed in children experiencing multiple clinical
episodes during that same time period (idem Figure 9D).
In nine out of 10 subjects in whom peripheral blood par-
asites collected at diagnosis of the clinical malaria episode
were genotyped, the three allelic families were detected,
and one individual harboured only 2 allelic families. In
all 10 cases, infection with an allele against which there
was no evidenced pre-existing response did not elicit any
long lasting novel antibody specificity.
Long term temporal analysis of the response to MSP1-
block2
To analyse antibody patterns over several years, we used
archived systematic blood samples collected during the
longitudinal survey. Confirming a previous study in this
village [27], once acquired, the response to MSP1-block2
was essentially fixed over time. A typical example is shown
in Figure 10, where a 6-year follow-up was carried out on
child 01/13, starting at 6 months of age. The child had
been exposed to a mean of 200 infected bites each year
over the six years. A single peptide pool was recognised by
this child from the age of 2.5 years onwards (Figure 10A).
The intensity of the signal fluctuated subsequently,
including a drop during malaria attacks [e.g. the 2/11/98
Typical profiles of the temporal evolution of MSP1 block2-  specific IgG before and after the 1998 rainy season Figure 8
Typical profiles of the temporal evolution of MSP1 
block2- specific IgG before and after the 1998 rainy 
season. Antibodies were assayed from 25 individuals in 
August 1998 (yellow) and December 1998, i.e. after a rainy 
season when each inhabitant was exposed to a mean of 170 
infected bites. Anti-MSP1 block2 specific IgG was assessed by 
ELISA on 16 pools of biotinylated peptides. The upper, cen-
tral and lower panels show a representative example of a 
reduction of specific antibodies, an essentially unchanged 
profile, and a boosting of pre-existing responses, respec-
tively.BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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Temporal fluctuation of MSP1 block2- specific IgG during the 1998 rainy season Figure 9
Temporal fluctuation of MSP1 block2- specific IgG during the 1998 rainy season. Antibodies were assayed on 16 
pools of biotinylated peptides (sequence and composition of the pools described in Table 5). Typical individual patterns are 
shown, with the dates of blood sampling shown on each graph. A) Transient boosting of a pre-existing response in a 14 y old 
subject (code 11/21), who had a clinical malaria attack on 29/10/98. B) Transient loss of a pre-existing response in a 5 y old 
child (code 8/15), who had a clinical malaria attack on 28/08/98. C) Transient acquisition of a novel specificity in a 9.5 y old child 
(code 02/04), who had a clinical malaria on 10/09/98. D) Transient changes in a 5 y old child (code 03/18), who experienced 
three successive clinical episodes during that time period on 17/09/98, 22/10/98 and 11/12/98. For each cinical episode, an anti-
malarial treatment was administered to the patient on the day of diagnosis.BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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blood sample, which was collected on the day a malaria
episode was diagnosed presented a lower signal than the
preceding (23/10/98) and following (4/12/98) samples],
but nevertheless there was a progressive increase with
cumulated exposure. Analysis of fine specificity on the
individual constituents of peptide pool 11 showed the
same pattern for all positive samples collected from this
child with recognition of peptides # 46, 61 and 74,
namely of the K1-specific block1-block2 junction (Figure
10B). The occurrence of clinical malaria episodes in this
child resulted in temporarily reduced signals (hence anti-
body levels), but was not associated with stable acquisi-
tion of any novel specificity.
Discussion
This first detailed longitudinal survey of Pfmsp1 block2
sequence polymorphism along with the assessment of the
specific humoral response within a single endemic setting
provides novel insights on the locus at the population
level and on the possible selective forces underpinning
such a polymorphism. A very large local polymorphism
was detected, mainly due to microsatellite type variation,
resulting in a very large number of low frequency alleles.
Numerous novel alleles were identified here, including
novel MR alleles, illustrating the value of in depth analysis
of local polymorphism. The humoral response of the vil-
lagers, as deduced from the reaction with a series of 15-
mer peptides, displayed features that illuminate its possi-
ble role in selection for diversity. The relative distribution
of the family-specific antibody responses mirrored the rel-
ative distribution of the family types at the parasite popu-
lation level. Seroprevalence was moderate. Responses
were usually limited to a single family and frequently
directed to family-specific sequences present in most of
the alleles from that family circulating in the village. This
is consistent with a frequency-dependent selection operat-
ing at the family level. However, the serological analysis
did not outline frequent occurrence of immune responses
possibly selecting for sequence variants within that fam-
ily. It confirmed and expanded on previous observations
in this setting [27] of an essentially fixed antibody specif-
icity, despite intense exposure to a very large number of
Serological longitudinal follow up of child 01/13 from 6 months to 6 years of age Figure 10
Serological longitudinal follow up of child 01/13 from 6 months to 6 years of age. Antibodies were assayed on 16 
pools of biotinylated peptides (A) and to each individual peptide from positive pool 11 (B). The peptide sequence and compo-
sition of the pools are described in Table 5. The dates of blood sampling are shown to the right of the graph. A. reactivity on 
the peptide pool. B. reactivity of three representative blood samples on individual peptides from pool 11.BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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allelic types. Overall, the data point to a possibly anti-
body-driven diversifying selection maintaining balanced
family types within the population, as proposed by other
groups [3,12,23,24,28,33] but do not support the com-
monly accepted notion that the families accumulate
mutations that allow the parasite to circumvent the host's
capacity to build up an efficient immune response select-
ing for sequence variants.
The study design used here differs from previous studies
in combining assessment of actual sequence polymor-
phism with analysis of sequence-specific immune
response rather than combining PCR fragment size poly-
morphism with assessment of antibody responses using
recombinant antigens [3,23,25,28,31-33]. No significant
temporal fluctuations of the relative distribution of the
allelic families was found over the 10-year period investi-
gated, consistent with longitudinal studies in The Gambia
using monoclonal antibody serotyping [42], and in Viet-
nam using PCR-based genotying [20], differing in this
regard from studies conducted in Brazil [28,43]. The fam-
ily distribution obtained here for symptomatic, high den-
sity infections was superimposable with the distribution
observed in previous cross-sectional surveys of asympto-
matic infections [44] [see Additional file 11]. Sequencing
showed a very large number of low frequency genetic var-
iants, along with one dominant allele (RD0) and few
intermediate frequency alleles (DK65, RD5, DM11). Only
29 out of 126 alleles were detected at a frequency above
1%. The level of polymorphism of the non repeated R033
family was similar to the level observed in the same set-
ting for Pfmsp4, in however a much smaller (30-fold
lower) sample size [45]. Tests for neutrality did not show
a significant departure from neutrality, for the repeated
domains of the K1-, Mad20- and MR- types and for the
repeatless RO33 family. The Tajima's test for RO33 is con-
sistent with selectively neutral mutations [46]. Testing the
repetitive sequences for selection is difficult, since the
mutational and evolutionary processes underlying their
diversification are not clearly understood. The Ewens-
Watterson (E-W) [38] test is based on the idea that, under
neutrality, the observed number of alleles should be con-
sistent with the observed gene diversity. Because of their
particular mutation patterns and rates, neutral microsatel-
lites tend to show naturally more alleles than expected
from their observed gene diversity [47]. This phenome-
non could artificially reduce the effect of balancing selec-
tion on allele distribution and as such reduce our ability
to detect it. However, the effect of repeated mutations on
the distribution of alleles is most of the time rather small
and occurs mainly when the observed gene diversity is low
which is not the case for MSP1 repeat domains [47].
Hence, if a strong balancing selection is acting on the
MSP1 repetitive sequences, we should still be able to
detect it. Furthermore, the reported evidence for diversify-
ing selection on the Pfmsp1 block2 locus [3] included the
analysis of such repeat-related polymorphisms. When
considering fragment size polymorphism, there was no
evidence of departure from neutrality either, contrasting
with a recent report from Kenya [16], where a different
parasite population sampling strategy was used. The 306
samples successfully genotyped here originated from 229
different villagers (approx. 85% of the village inhabitants,
with all age groups included) over a decade, whereas the
362 samples analysed in Kenya were collected by repeated
sampling from 45 infants during a 4y period [16]. Such
repeated sampling from the same sub-group may have
biased the analysis of population polymorphism, in par-
ticular as successive clinical malaria attacks experienced
by a child are each caused by "novel" parasite genotypes
[48].
To assess the consequence of sequence diversity on anti-
genicity, and in the search for evidence of antibody-driven
diversifying selection, we opted here for the use of syn-
thetic peptides encompassing a large number of sequence
variants, rather than using recombinant proteins express-
ing an entire MSP1 block2 domain, which exposes multi-
ple antigenic determinants. Whereas recombinant
proteins allow to study family cross-reactivity, recognition
at the single epitope level is best monitored using syn-
thetic peptides. Individual MSP1 epitopes are displayed
by short peptidic sequences, which are recognised by
monoclonal antibodies [15] and human sera [15,26,27].
Use of synthetic peptides may result in underrepresenting
certain epitopes, including conformational epitopes, and
hence in underestimating the overall seroprevalence to
the locus. However, interestingly this assessment using
synthetic peptides outlined a strikingly similar relative
distribution of family genotypes and family-specific anti-
bodies in Dielmo, consistent with observations in other
settings monitoring immune responses using recom-
binant proteins [3,23,25,28,29,31-33,36].
The humoral response of the Dielmo villagers suggested a
family-specific selection pressure rather than an antibody-
mediated selection for sequence variants. Seroprevalence
increased with age, but the number of peptides recognised
was unrelated to age. Most individuals had antibodies to
one family only, and within that family, polymorphic
sites as well as common repeat motifs and the more con-
served family-specific sequences were recognised. Impor-
tantly, antibody specificity remained essentially fixed over
time. Confirming previous observations in this setting
[27], the long term longitudinal follow up showed that
cumulated exposure to an increasing number of Pfmsp1
block2 alleles was usually not associated with stable
acquisition of antibody specificities to additional
sequence variants. Analysis of anti-MSP1 block2
responses during a transmission season showed that some
individuals experiencing a high density clinical episode
had their pre-existing responses boosted, while antibodiesBMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
Page 18 of 25
(page number not for citation purposes)
were transiently undetectable in other patients. In some
cases, novel specificities were acquired only transiently,
since they were rarely detected a few weeks after the epi-
sode and undetected in subsequent longitudinal sam-
plings, where a steady state, essentially stable specificity
profile was consistently observed. The response pattern to
MSP1 block2 markedly differs from the progressively
enlarging antibody repertoire to erythrocyte surface vari-
ant antigens (see [49] and references therein). This rather
stable steady state specificity profile is highly reminiscent
of clonal imprinting. It may reflect particular constraints
on the response or stimulation by chronic asymptomatic
carriage and/or novel infections, quite frequent in such a
holoendemic setting. Clonal imprinting of responses to
another P. falciparum merozoite surface antigen display-
ing variable repeats, namely MSP2 has been suggested in
some studies [50,51], but was not supported by studies on
PfMSP1block2 responses in a hypoendemic Sudanese set-
ting [25]. The best evidence in favour of clonal imprinting
in malaria parasites stems from studies on cellular
responses to peptide variants of the CS protein [52].
Studies conducted in other African settings, using recom-
binant proteins, have outlined several features that are
consistent with the observations we made in Dielmo: i) a
moderate seroprevalence to MSP1 block2 that increases
with age [3,24], ii) recognition of a single family by a large
proportion of responders [3,25,30], iii) family-specific
and sub-type specific responses [3,23-25] along with rec-
ognition of conserved family-specific flanking domains
[23,24]; iv) transient acquisition antibody specificity or
loss of pre-existing response during a malaria attack
[24,25]. Thus in other African settings as well, the MSP1
block2-specific humoral response is unlikely to exert a sig-
nificant selection favouring the outgrowth of parasites
presenting mutant epitopes. This does not rule out a selec-
tion by cellular immune effectors, which has not been
assessed here. This deserves a detailed study, since
sequence variation of the block1-block2 junction has
been shown to influence cellular responses [53].
Confirming studies in other areas [3,23,24], the antibod-
ies to one or more MSP1 block2 allelic families were pro-
spectively associated with protection against subsequent
clinical attacks. However, multivariate analysis showed
this association to be confounded by age, and as such dif-
ficult to distinguish from concomitant acquisition by
Dielmo villagers of other responses involved in protec-
tion. Protection against clinical malaria has been indeed
associated with an array of antigens in various endemic
settings, including the antigenic variant PfEMP1 exposed
onto the infected red blood cell surface [54,55], msp1-19
[56], R23 [57], msp3 [58].
Apart from the RO33 types, the large sequence polymor-
phism observed in Dielmo was essentially of microsatel-
lite type. Variations within the K1, Mad20 and MR
families mainly focused on the second and third codon of
the tripeptide repeats, involving, furthermore, a restricted
set of amino acid residues. As noted by others [16], frag-
ment length did not adequately describe the local genetic
diversity. Based on size polymorphism, 55 alleles were
identified, but 126 alleles were identified by sequence
analysis. All six RO33 alleles had the same size. Some size
bins used to group alleles from other families turned out
to group a large number of distinct sequences (up to 11
for K1-types and up to 9 for Mad20 types) [see Additional
file 12].
Sequence analysis identified numerous novel alleles and
specific motif arrangements, with 113 of the 126 Pfmsp1
block2 allele sequences observed in Dielmo being novel.
The RO33 types displayed novel point mutation polymor-
phisms. Compared to the reported sequences, the K1 alle-
les from Dielmo were more diverse (higher number of
distinct motifs), with more frequent usage of motifs 3 and
4, and with a novel K1-type motif encoding the SVT
tripeptide (7). The Mad20 types were longer (more
repeats per allele), used a restricted set of codons and par-
ticular motifs, with a higher occurrence of SGG-encoding
motifs, more frequent use of motif 8 and fewer motifs 7
and 4. The MR family accounted for up to 13.3% of all
Pfmsp1  block2 alleles from Dielmo, a lower frequency
than the 28-29% observed in a Kenyan holoendemic set-
ting [11,16]. We could not identify any epidemiological
parameter associated with the presence of MR alleles:
there was no association with age, gender, ABO or Rhesus
blood group. Interestingly, like the other three families,
MR alleles from Dielmo presented specific characteristics.
All harboured a RD5-type RO33 moiety, differing from
most MR alleles with a worldwide distribution [11,16].
Furthermore, DMR1 displayed a novel MR subtype with a
5 7 5 motif (Mad20 sub-group 1c) instead of a 8 7 5 motif
(Mad20 sub-group 2c). In addition, a novel hybrid with a
3' RO33/K1 hybrid sequence was observed. Whether this
DMRK allele was generated by insertion of a SPPADA-
encoding DNA segment within a MR allele (possibly
MR6), or whether this element was inserted within RD5
before recombination with a Mad20 allele is unclear.
Insertion of the SPPADA-encoding segment within any
allele of the RO33 family has never been reported, but was
observed within the K1-type in this study (allele DK67)
and in other settings [9]. Observation of a single RO33
progenitor together with a single Mad20 progenitor led
Takala et al [16] to propose that the MR family arose from
a single recombination event. The present data rather sug-
gest that several separate recombination events involving
distinct RO33-types and Mad20-types progenitors have
contributed to the generation of this hybrid family.
The characteristic of the Pfmsp1 block2 allelic repertoire in
Dielmo is in line with the epidemiological conditions pre-BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
Page 19 of 25
(page number not for citation purposes)
vailing in the village. Unlike the surroundings where trans-
mission is moderate and highly seasonal, transmission in
Dielmo is perennial and intense [59]. Therefore, local
transmission largely dominates over the import of alleles
from the neighbouring area during the 9-10 months of the
dry season. As such, Dielmo constitutes a transmission area
where a high level of genetic diversity can be maintained.
Detailed analysis of parasite population structuring and
expansion in this setting awaits study of additional genetic
loci. Transmission in the village occurs throughout the year,
albeit with marked seasonal fluctuation in entomological
inoculation rates and vector species [59]. The seasonal pat-
tern of family distribution may reflect different fitness/sur-
vival rates associated with different allelic families under
different transmission conditions and/or for different
Anopheline vector species. Additional studies are needed to
explore this hypothesis further.
Previous studies have surveyed sequence polymorphism
across large geographic areas or with a small sample size in
a single setting, and as such did not capture the micro-geo-
graphic features observed here in a single setting. Better
understanding at micro-geographic level is essential to ana-
lyse immune responses in the context of the parasite popu-
lation to which people are exposed. This is critical
importance to interpret selective forces on parasite popula-
tion, and to design rationale control measures accordingly.
Conclusion
The Pfmsp1 block2 locus presents a population sequence
diversity larger than we could anticipate from published
studies. A very large local polymorphism was detected,
mainly of microsatellite type. The humoral response
observed here using synthetic peptides was consistent
with a frequency-dependent selection operating at the
family level. However, there was no evidence for major
humoral selection for sequence variants. In contrast, anti-
body specificity remained fixed over time, despite expo-
sure to novel allelic forms. Such a lack of stable
acquisition of novel antibody specificities in response to
novel infecting types is reminiscent of clonal imprinting.
The locus appears under antibody-mediated diversifying
selection in a variable environment that maintains a bal-
ance between the various family types without selecting
for sequence variant allelic forms. At the family level,
intra-family sequence diversity is consistent with a neutral
evolution and with the observed characteristics of the
antibody response. Finally, the data reported here do not
confirm the association of the acquired humoral response
to MSP1 block 2 with protection against subsequent clin-
ical P. falciparum malaria attacks.
Methods
Study site and patient recruitment
Dielmo, located in Sine Saloum, Senegal, is a village of
approximately 250 inhabitants, where malaria is holoen-
demic. In 1990, the entire village population was enrolled
in a longitudinal prospective study described in detail
elsewhere [60]. The main vectors in the village are Anoph-
eles gambiae s.s. and An. funestus [59]. Informed consent
was obtained from each adult participant and from par-
ents or legal guardians of each child at the beginning of
the study and was renewed on a yearly basis. Individuals
could withdraw from the study at any time. Each year the
project was reviewed and approved by the Joint Ministry
of Health and Pasteur Institute Surveillance Committee.
The retrospective analysis has received ethical clearance
from the National Ethical Committee of the Republic of
Senegal.
Parasite samples
We studied here 336 samples collected from mild malaria
episodes selected from the existing collection of frozen
blood samples and analysed for drug resistance markers
[61]. The sampling strategy was as follows: From a list of
approx 3,400 samples collected longitudinally during a
malaria episode, samples were chosen for molecular anal-
ysis so as to survey the largest possible panel of villagers.
Since in this hyperendemic setting the heaviest clinical
malaria burden is in the <10 y olds and since some chil-
dren are more susceptible than others [62], we needed to
avoid iteration bias due to the increased susceptibility of
some individuals. This reduced the risk not only of over-
representing certain genotypes to which some individuals
might be more susceptible than others, but also of overes-
timating polymorphism, because each of the successive
clinical malaria attacks experienced by one person is
caused by "novel" parasites [48]. We therefore set an inter-
val of >3 years between two samples from the same indi-
vidual, with the further restriction that no person could
contribute with more than three samples in all. The
number of samples studied each year is indicated in Table
1. Of the 336 samples selected, 306 were genotyped for
Pfmsp1 block2. They originated from 229 villagers, with
159, 63 and 7 villagers contributing once, twice and three
times, respectively, to the panel of Pfmsp1 block2-positive
samples studied here. This included 120 males and 109
females [159 and 147 males and females, respectively,
among the panel of samples studied]. The mean age ±
standard deviation at the time of blood sampling was 11.5
± 13.36 years (minimum = 0.3 y, maximum = 89.7 y,
median = 7.3 y, Q25-Q75 = 3-13.9 y). [Mean age of males
12.08 y median age 6.9 y; mean age of females 10.82 y;
median 7.9 y]. There were 275, 5, 29 and 1 samples from
villagers with an AA, AC, AS and SS haemoglobin type (six
of unknown type). The samples were from 31 out of the
34 village compounds.
Pfmsp1 block2 genotyping by nested PCR
Frozen blood samples were thawed and extracted with
phenol-chloroform [48] and stored at -20°C until use.
Pfmsp1 block2 was amplified by semi-nested PCR in a 50BMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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μL reaction volume containing 5 μL DNA, 50 mM KCl, 1.5
mM MgCl2, 10 mM Tris-HCl pH 9.0, 200 μM dNTP, 5 U
Taq Polymerase (Amersham Pharmacia), 1 μM of each
primer. For the first PCR, the conserved primers used were
Fmsp1uf 5'GAAGATGCAGTATTGACAGG and Fmsp1ur
5'CATTAATTTCTTCATATCCATC. A first denaturation step
at 96°C for 5 min was used, followed by 25 cycles of dena-
turation at 96°C for 1 min; hybridization at 64°C for 90
sec, extension at 72°C for 45 sec with a final extension at
72°C for 7 min. The semi-nested PCR was carried out
using a forward family specific primer and the reverse con-
served primer Fmsp1ur under the same conditions for 25
cycles except that the annealing was done at 68°C. The
sequence of the forward family-specific primers was k1ff
5'ATGAAGAAGAAATTACTACAAAA, mad20ff 5'GAAG-
GAACAAGTGGAACAGC and ro33ff 5'TACTCAAGTTGTT-
GCAAAGC. PCR products were analysed on 1.5%
Nusieve:agarose gels (1:3). The size of the bands was eval-
uated using a 100 bp DNA ladder (Bio-Rad) as size mark-
ers. Alleles were classified in 10 bp bins. A Pfmsp1 block2
genotype could be generated for 306 of the 336 samples.
Of the 30 negative samples, one had a poor DNA quality
(negative PCR for five loci tested), but the other 29 gener-
ated PCR products for other loci (Pfcrt, Pfdhfr-ts and mic-
rosatellite loci). Whether the failure to amplify Pfmsp1
block2 was due to polymorphism within the primer
sequence or a lower sensitivity of the reaction as com-
pared to the other loci is unknown. These DNAs were
excluded from the analysis.
In the case of mixed infections where different alleles
belonging to the same family were detected by size poly-
morphism, the bands of different size were excised from
the agarose gel, re-amplified with specific primers to
recheck the allele type.
Sequencing
PCR products obtained by semi-nested PCR using family
specific forward primers were directly sequenced. All
Pfmsp1 block2-derived PCR products were purified using
polyacrylamide P-100 gel (Bio-Gel, Bio-Rad, 150-4174)
on 96 well plates equipped with a 0.45 μm filter (96 well
format, Millipore,1887, ref MAHVN4550). The purified
product was quantitated by comparing it with DNA quan-
titation standards (Abgene® QSK-101) after electrophore-
sis on 1.2% agarose gel. The sequencing reaction
contained 2 μl of PCR product (≥ 20 ng), 1.25 μL 5×
Buffer, 1.5 μL BigDye v3.1, 2 μL of 2 μM primer in a 10 μL
final volume. Amplification was performed in a
GeneAmp9700 (Applied Biosystem) [1 min at 94°C fol-
lowed by 35 cycles of (10 sec at 96°C, 5 sec at 50°C and
4 min at 60°C), and held at 4°C. The products were then
precipitated and sequenced on both strands using an ABI®
prism 3100 DNA analyzer as described [61]. There were a
few cases where sequencing of the excised band proved
not possible because of ambiguity in base calling, proba-
bly reflecting mixture of alleles with similar size. These
samples were discarded from the analysis. We retained in
the analysis only sequences where base calling was non
ambiguous and the signal accounted for more than 95%
of the signal for each individual base.
False recombinant alleles can be generated during PCR as
a result of template switching, when long amplicons are
generated, namely Pfmsp1 blocks 2-6, with cross-over sites
identified in the distal part of block 3 and in block 5 [63].
To reduce the risk of this potential pitfall, short regions
were amplified (i.e. upstream from the identified cross-
over sites), with PCR anchored in conserved regions but
relatively close to the junction with polymorphic
sequences. Second, we verified absence of undesired
amplification from deliberate mixture of reference alleles
using the semi-nested PCR strategy The PCR fragments
were sequenced and all were perfect match with the
reported sequence.
Accession numbers are as follows: [Genbank: EU032016-
EU032159, EU032160-EU032227, EU032227-
EU032246, EU037095, EU032250-EU032276 and
EU032248] for the DK, DM, RD0, RD1-5, DMR and
DMRK sequences, respectively.
Sequence analysis
Pfmsp1  block2 alleles deposited in Genbank were
retrieved by repeated blasting using each individual 9-mer
nucleotide sequence observed in K1-type or Mad20-type
alleles and the full length RO33-type block2 sequence. In
addition, K1 alleles reported by Tetteh et al [15] originat-
ing from Zambia were included. The curation indicated by
Miller et al [8] was included when needed. The various
alleles were aligned using ClustalW and curated manually.
Redundant alleles were discarded. This resulted in overall
59 distinct K1-type [see Additional file 5], 52 Mad20-type
[see Additional file 6], four RO33-type [see Additional file
3] and nine MR-type alleles [see Additional file 7]. The
alleles from Dielmo were compared to the reported alleles
for the structure of the microsatellites: frequency of the
individual tripeptide motifs, overall number of repeats,
numbers of each individual tripeptide and combinations
thereof (dimers, trimers and tetramers).
Neutrality tests
Allele distribution was analysed using the Ewens-Watter-
son-Slatkin (EWS) tests [38,39]. The test was applied con-
sidering a family as a single allele (i.e. grouping all alleles
from that family together) or by considering individual
alleles within each family independently. Individual alle-
les were then classified 1) by size and nucleotide sequence
polymorphism or 2) by size polymorphism alone. Ewens-
Watterson tests were performed using the software Pypop
[64]. Nucleotide diversity within the RO33 family was
analysed using Tajima's D test [40] and Fu and Li's testBMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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[41] from DnaSP version 4.0 software developed by Rozas
et al [65].
Serological analysis
Archived sera, collected throughout the longitudinal fol-
low up were used. Seroprevalence was studied using 243
plasma (i.e. 95% of the village population) collected dur-
ing a cross-sectional survey conducted on 2-3 August 1998
at the beginning of the rainy season (27, 25, 26, 40 46 and
79 in the 0-2 y, 3-5, 6-8, 9-14, 15-24 and ≥25 y age groups,
respectively). A subset of 25 sera collected in December
1998 from individuals whose August 1998 scored positive
for antibodies to one or more MSP1-block2 derived pep-
tides was analysed. A follow up of ten individuals during
the 1998 rainy season was carried out using the monthly
fingerprick blood samples collected on a systematic basis
together with a fingerprick sample collected on diagnosis
of clinical malaria when available. The entomological
inoculation rate during the August-December 1998
period, assessed as described [59], was 170 infected bites/
person. In addition, archived sera from children, collected
longitudinally during the survey were used to follow the
acquisition of antibodies over a period of several years.
A set of 82 15-mers derived from MSP1 block2 tripeptide
repeats and the family-specific flanking region was syn-
thesized by Chiron Mimotopes Pty. Ltd. (Clayton, Victo-
ria, 3168, Australia). There were 34, 31, and 12 K1-
Mad20- and RO33-specific sequences. In addition, 5 pep-
tides derived from the junction with block1 were used.
The peptide sequences are described in Table 5. The pep-
tides represented the tripeptide combinations observed in
Dielmo for the K1 and Mad20 families [see Additional file
9]. These peptides were synthesized with an N-terminal
biotin group separated from the peptide sequence by a
SGSG spacer and with an amidated C-terminus. All pep-
tides were soluble. A similar set of peptides was used to
explore the humoral response in Dielmo villagers in pre-
vious studies [26,27]. Based on these results, which
showed a restricted specificity, and in view of the limited
volume available for several sera, we first screened indi-
vidual sera using 16 peptide pools (4-6 peptides per pool
as described in Table 5) and in a second step analysed the
reactivity of the positive sera on individual peptides from
each positive pool. ELISA was performed on streptavidin-
coated plates with either pools of 0.1 nM each bioti-
nylated peptides or 0.5 nM biotinylated peptide adsorbed
in each well as described [27]. We checked with control
mouse sera and individual human positive controls that
peptide dilution within the pool of peptides did not mod-
ify the outcome of specificity analysis. Human plasma was
tested in duplicate at a 1:500 dilution and bound IgG or
IgM was measured using horseradish peroxidase-conju-
gated goat F(ab')2 to human IgG Fc (γ) or to human IgM
Fc (μ) (Cappel, Organon-Technica, Turnhout, Belgium).
Optical density (OD) was measured on an Emax reader
(Molecular Device) at 450 nm. Control wells without pep-
tide were used to check for potential anti-streptavidin
antibodies. The wells that gave a signal twice the OD value
of the wells without peptide were considered positive. IgG
subclass analysis was performed as described [27].
Association with protection
This was done based on the data gathered during the lon-
gitudinal survey protocol and available in the database.
Daily clinical surveillance was carried out over the August-
December 1998 follow-up period, as described [60,66].
Each villager was visited at home for clinical surveillance
and blood films were made in case of fever. The protocol
included the notification of all febrile episodes to the
medical staff and the controlled use of anti-malarial
drugs. A malaria attack was defined as an association of
symptoms suggesting malaria with parasitaemia above an
age-specific threshold as described [66,67]. An anti-malar-
ial drug cure was administered by the medical staff in all
cases of malaria attacks. Procedures to estimate associa-
tion with protection have been described [56,57,68]. In
brief, the number of clinical malaria attacks experienced
during the follow-up was analyzed as the dependent vari-
able in a Poisson regression model, using the number of
days of presence in the village as exposure variable. The
association between the incidence of clinical malaria
attacks and independent variables, i.e. presence of anti-
bodies to allelic families, age, haemoglobin type or ethnic
group, was tested.
Statistical analysis
Yearly distribution of the 524 PCR fragments by allelic
family was analysed by Pearson Chi2 with the assumption
that the alleles co-infecting the same individual were inde-
pendent. Allelic family distribution by gender, age, Hb
type, ABO group, Rhesus group and by month was ana-
lysed by Fisher's exact test. The allelic family infection rate
(percentage of infected individuals harbouring one or
more alleles from that family) by gender, β-globin type,
ABO or Rhesus blood group, by age (0-1 y, 2-5 y, 6-9 y, 10-
19 y and ≥20 y) and by season in the year was analysed by
Fisher's exact test. For the analysis of seasonality, the year
was divided into three periods based on the rains, the vec-
tors present and the entomological inoculation rate. The
mean entomological inoculation rate was 32, 140 and 39
infected bites/person/year in February-May (dry season),
June-October (rainy season), and November-January,
respectively.
The estimated multiplicity of infection was first analysed
using a zero-truncated Poisson regression model, with the
assumption of a constant probability to detect an addi-
tional allele in a homogeneous carrier population. The
mean predicted estimated moi was 1.193 allele/infected
individual. The predicted distribution was calculated,
grouping the classes with estimated moi ≥ 4 and did notBMC Microbiology 2009, 9:219 http://www.biomedcentral.com/1471-2180/9/219
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differ from the observed one (51.6% vs. 51.9%, 29.4% vs.
31%, 15.0% vs. 12.3%, 3.9% vs. 3.7% for observed vs.
predicted estimated moi 1, 2, 3 and ≥4, respectively (Chi2
test, 3 df ≥ 2.53, p = 0.47). Estimated moi distribution by
age group (0-1 y, 2-5 y, 6-9 y, 10-19 y and ≥20 y), gender,
Hb type, ABO group, Rhesus blood group, year, month of
the year and season was analysed by non parametric
Kruskal-Wallis test.
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Additional file 1
Distribution frequency of Pfmsp1 block2 fragment size in Dielmo, 
Senegal. This file shows the frequency of alleles by fragment size for the 
K1 and MAD20 types (the RO33 alleles did not display fragment size pol-
ymorphism). The locus was amplified by semi-nested PCR and PCR prod-
ucts were analysed on 1.5% Nusieve:agarose gels (1:3) and visualised by 
ethidium bromide staining. The size of the bands was evaluated using a 
100 bp DNA ladder (BioRad) as size markers. Alleles were classified in 
10 bp bins.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2180-9-219-S1.PDF]
Additional file 2
Temporal distribution of Pfmsp1 block2 allelic families as assessed by 
nested PCR and sequencing. This file shows the relative distribution of 
the various allelic families by year as assessed either by PCR genotyping or 
gene sequencing. The number of samples genotyped and the number of 
sequences generated for each calendar year are indicated in Table 1. 
Sequences were determined from single PCR bands generated by family-
specific nested PCR. Each sample was tested in three parallel PCR reac-
tions triggered by one forward family specific primer and a reverse univer-
sal primer. Only the reactions generating a single band (estimated by size 
on agarose gels) were processed for sequencing.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2180-9-219-S2.PDF]
Additional file 3
Pfmsp1 block2 RO33-types deposited in the Genbank database. This 
file lists the Genbank accession number of the deposited RO33-type alle-
les, along with the country of origin of the samples, and the sequence in 
single amino acid code. For references see the main text.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2180-9-219-S3.PDF]
Additional file 4
Sequence analysis of the Dielmo alleles and comparison with the alle-
les reported in the literature and in the databases. This file provides a 
detailed analysis of the molecular variation of the repeat motifs (number, 
sequence and arrangement) and of the point mutations observed in the 
various alleles from Dielmo and a comparative analysis with the alleles 
deposited in Genbank.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2180-9-219-S4.RTF]
Additional file 5
Pfmsp1 block2 K1-types deposited in the Genbank database or pub-
lished in the literature. This file lists the Genbank accession number of 
the deposited K1-type alleles, along with the repeat motifs coded as indi-
cated. 59 distinct alleles were identified, numbered 1-59. Several alleles 
have been observed in multiple settings and/or on multiple occasions. The 
geographic origin is shown, when indicated in the deposited sequence or 
in the corresponding publication. The codes used for the tripeptide repeats 
are shown below the table.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2180-9-219-S5.PDF]
Additional file 6
Pfmsp1 block2 Mad 20-types deposited in the Genbank database. This 
file lists the Genbank accession number of the deposited Mad20-type alle-
les, along with the repeat motifs coded as indicated. 52 alleles were iden-
tified, numbered 1-52. Note that several alleles have been observed in 
multiple settings and/or on multiple occasions. The geographic origin is 
shown, when indicated in the deposited sequence or in the corresponding 
publication.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2180-9-219-S6.PDF]
Additional file 7
Pfmsp1 block2 MR-type alleles deposited in the Genbank database. 
This file lists the Genbank accession number of the deposited Mad20/
RO33-hybrid alleles, along with the repeat motifs coded as indicated. The 
geographic origin is shown, when indicated in the deposited sequence or 
in the corresponding publication.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2180-9-219-S7.PDF]
Additional file 8
Published Pfmsp1 block2 alleles observed in Dielmo, Senegal. This file 
lists the previously described alleles that have been detected in Dielmo in 
this study. The name, Genbank accession number and geographic origin 
of the alleles deposited are indicated alongside the Dielmo alleles.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
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